GlaxoSmithkline Pharmaceuticals Limited (BSE:500660) is looking to sell some of its non-core brands as the company looks to consolidate its position in the chronic and vaccine segments, according to people directly aware of the development. The move is expected to mop up around INR 1 billion for the drug maker which is seeking to accelerate growth in the competitive Indian domestic pharma space that witnessed price cuts to court rulings on the sale of certain fixed-dose combination drugs. GSK has approached FDC Pharma, Piramal Enterprises Limited (BSE:500302) and Strides Pharma Science Limited (NSEI:STAR).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
886.6 INR | -1.14% | +1.12% | +36.55% |
04-30 | Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director | CI |
04-09 | Strides Pharma Science Gets US FDA Nod for Fluoxetine Tabs | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,094 INR | -0.46% | -1.82% | 4.25B | ||
962 INR | +2.05% | +4.00% | 2.59B | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.55% | 977M | |
+19.98% | 43.48B | |
+20.67% | 22.65B | |
+14.56% | 14.73B | |
+14.32% | 13.79B | |
+44.72% | 12.04B | |
-8.37% | 7.08B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+11.90% | 5.47B |
- Stock Market
- Equities
- STAR Stock
- News Strides Pharma Science Limited
- GSK Pharma Reportedly Plans To Sell Non-Core Brands